PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re: Partner Company

7 Nov 2006 10:24

Amphion Innovations PLC07 November 2006 Amphion Innovations Partner Company Durham Scientific Crystals Closes £875,000 Financing London, UK - 7 November 2006 - Amphion Innovations plc today announces that itsPartner Company, Durham Scientific Crystals Ltd. (DSC), a Durham Universityspin-out developing state-of-the-art semiconductor materials for the medicalimaging and security imaging markets, has raised an initial £875,000 at £2 pershare for the first close of a larger Series F financing. Amphion now owns 26.3%of Durham Scientific Crystals which is now valued at £8.3m post money. DSC has developed a breakthrough technology that is significant in thetransition from analogue to digital x-ray imaging. The Company hascommercialised the use of materials based on cadmium telluride, the premierchoice for use as digital detectors of x-rays and gamma rays, and will allow forsignificantly improved imaging in markets such as airport security and medicalimaging. Cadmium telluride materials are currently too expensive and too difficult toproduce to be used in large scale commercial applications. DSC, however, hasdeveloped a breakthrough production method to produce these crystals from avapour phase, rather than the conventional liquid based techniques, enabling thecrystals to be produced at an attractive cost and quality enabling their largescale commercial use in the future. The transformation to digital x-ray scanners in security imaging will be asignificant improvement as the technology will allow much faster screening anddirect 'fingerprinting' of dangerous materials such as liquid bombs and plasticexplosive, which are currently hard to distinguish from other plastics. In medical imaging, cadmium telluride will offer significant advantages over thecurrent materials including greater sensitivity to x-rays to enable fasterimaging and lower dosing, and will increase the ability to understand diseases,such as Alzheimer's and Cancer, and detect them in their early stages, The capital raised in this latest round of financing will support continuedresearch and development, staffing and overhead expenses. DSC is also workingwith non-commercial partners to optimise its crystals with electrode technologythat makes it easier to integrate them into the electronic infrastructure ofscanners. Richard C.E. Morgan, Chief Executive Officer of Amphion, said: "Due to the recent security issues in our airports, and the continued desire todiagnose and treat diseases earlier, there is a large growing need for faster,more effective and clearer digital imaging. We believe that DSC has thetechnology to meet these needs and this financing signifies that our investorsand partners see DSC as a company poised for tremendous growth and value thetechnology and recognise its prospects." Dr Arnab Basu, Chief Executive Officer of Durham Scientific Crystals, said: "We are excited by the response of the investment community and these funds willallow us to accelerate our R&D as we further continue to commercialise ourproducts to significantly improve imaging in the security and medical markets." For further information please contact: Amphion Innovations plcJosh Berkman, Media Relations +1 (646) 747-7158 Financial Dynamics +44 207 269 7169Ben AtwellJohn Gilbert About Amphion Innovations plc Amphion Innovations plc is listed on the AIM Exchange in London under the symbolAMP. Amphion's business is the formation, financing, management and developmentof life sciences and technology companies, working in partnership withcorporations, governments, universities and entrepreneurs seeking tocommercialize their intellectual property. Durham Scientific Crystals, Ltd. Durham Scientific Crystals, Ltd. is a research and development company, whichwas spun-out from the Physics Department of the University of Durham. Thecompany was formed in April 2003 and has been actively involved in the researchand development of semiconductor materials, in conjunction with the Universityresearch labs. DSC's technological expertise is a result of over three decadesof semiconductor research at the University of Durham. DSC is located in Sedgefield, County Durham, England and is developingnext-generation proprietary products and processes based around keysemiconductor optoelectronic materials used in medical and securityapplications. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.